Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : VAR-037
| Cat. No. | VAR-037 |
| Description | Motolimod, also known as VTX-2337, is a selective TLR8 agonist that induces a response comparable with that of the receptor's natural ligand of viral single-stranded ribonucleic acid. In vitro studies have demonstrated that motolimod effectively activates TLR8, leading to enhanced NK-cell function, and in combination with cetuximab, increases tumor-directed ADCC. |
| Product Type | Toll-like Receptor Agonists |
| Alias | VTX-2337 |
| Purity | ≥98% |
| Storage | Store at -20°C in powder form. Store at -80°C once reconstituted. |
A: The powder form of this reagent can be stored at -20°C, and after dissolution, it needs to be aliquoted and stored at -80°C.
A: The EC50 of Motolimod is about 100 nM, inducing the production of TNFα (EC50: 140 nM) and IL-12 (EC50: 120 nM) in PBMCs.
A: No, Motolimod is a selective agonist of TLR8, which has at least 50 times higher selectivity for TLR8 than TLR7.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Motolimod in combination with cetuximab, increases tumor-directed ADCC.
The reagent Motolimod activates the TLR8 receptor and induces a response comparable to that of the receptor's natural ligand, viral single-stranded ribonucleic acid.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.